Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure

被引：0
|
作者：
Mateo Porres-Aguilar
Oscar C. Muñoz
Aamer Abbas
机构：
[1] Texas Tech University Health Sciences Center/Paul L. Foster School of Medicine,Department of Internal Medicine
[2] Texas Tech University Health Sciences Center/Paul L. Foster School of Medicine,Division of Cardiovascular Diseases
来源：
Current Cardiology Reports | 2016年 / 18卷
关键词：
Coronary artery disease; Ivabradine; Heart failure; Heart rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Increase in heart rate represents a significant contribution in the pathophysiology of coronary artery disease and heart failure, by promoting atherosclerotic process and endothelial dysfunction. Thus, it negatively influences cardiovascular risk in the general population. The aim of this review is to analyze the current, controversial, and future role of ivabradine as an anti-anginal agent in the setting of coronary artery disease without heart failure. Ivabradine represents a selective heart rate-lowering agent that increased diastolic perfusion time and improving energetics in the ischemic myocardium.
引用
收藏
相关论文
共 50 条
  • [41] The therapeutic role of ivabradine in heart failure
    Badu-Boateng, Charles
    Jennings, Robert
    Hammersley, Daniel
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2018, 9 (11) : 199 - 207
  • [42] Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate
    Tagliamonte, Ercole
    Cirillo, Teresa
    Rigo, Fausto
    Astarita, Costantino
    Coppola, Antonino
    Romano, Carlo
    Capuano, Nicola
    [J]. ADVANCES IN THERAPY, 2015, 32 (08) : 757 - 767
  • [43] Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate
    Ercole Tagliamonte
    Teresa Cirillo
    Fausto Rigo
    Costantino Astarita
    Antonino Coppola
    Carlo Romano
    Nicola Capuano
    [J]. Advances in Therapy, 2015, 32 : 757 - 767
  • [44] HEART FAILURE RISK FACTORS ANALYSIS ON STABLE CORONARY ARTERY DISEASE PATIENTS IN CHINA
    Chen, J.
    Wudong, G.
    Li, X.
    Wang, Y.
    [J]. VALUE IN HEALTH, 2020, 23 : S107 - S107
  • [45] Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease
    Eisen, Alon
    Benderly, Michal
    Behar, Solomon
    Goldbourt, Uri
    Haim, Moti
    [J]. AMERICAN HEART JOURNAL, 2014, 167 (05) : 707 - 714
  • [46] Predictors of heart failure in patients with stable coronary artery disease and preserved ejection fraction
    Lewis, Eldrin
    Jablonski, Kathleen A.
    Rice, Madeline M.
    Solomon, Scott D.
    Clemenza, Francesco
    Hsia, Judith
    Maggioni, Aldo P.
    Zabalgoitia, Miguel
    Huynh, Thao
    Pfeffer, Marc A.
    [J]. CIRCULATION, 2007, 116 (16) : 705 - 705
  • [47] ADIPONECTIN IS ASSOCIATED WITH INCREASED MORTALITY AND HEART FAILURE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
    Beatty, Alexis L.
    Zhang, Mary H.
    Ku, Ivy A.
    Na, Beeya
    Schiller, Nelson B.
    Whooley, Mary A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1120 - E1120
  • [48] Coronary artery disease and prevention of heart failure
    Klein, L
    Gheorghiade, M
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2004, 88 (05) : 1209 - +
  • [49] Heart failure as a manifestation of coronary artery disease
    Bonow, RO
    Gheorghiade, M
    [J]. CORONARY ARTERY DISEASE, 1998, 9 (10) : 623 - 624
  • [50] Ivabradine: Current and Future Treatment of Heart Failure
    Thorup, Lene
    Simonsen, Ulf
    Grimm, Daniela
    Hedegaard, Elise R.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (02) : 89 - 97
12345